The U.S. Supreme Court on Monday declined to hear Novartis Pharmaceuticals Corp's bid to revive a key patent on its blockbuster multiple sclerosis drug Gilenya that was invalidated amid a legal dispute with China's HEC Pharm Co Ltd.
The justices turned away an appeal by Novartis of a lower court's decision to cancel the patent, a ruling that paved the way for some generic versions of Gilenya.
https://finance.yahoo.com/news/us-supreme-court-rebuffs-novartis-133048462.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.